Quick answer
Who discovered GHK-Cu and what are the research milestones? The tripeptide glycyl-histidyl-lysine was studied by Pickart and colleagues from the early 1970s as a growth-modulating plasma factor (1973, 1979). A 1980 Nature paper proposed that it acts by facilitating copper uptake into cells, and a 1982 spectroscopic study defined the structure of its copper(II) complex in solution. Fibroblast-culture work followed (2000), and review articles from 2008 to 2018 gathered the tissue-remodeling, antioxidant and gene-expression literature. The GHK-Cu product is supplied for laboratory research use only.
Short histories of GHK-Cu tend to blur dates and claims. This article follows the primary and review literature in order, says what each paper reported and notes what it did not. It is a history of research, not of any application, and it makes no claim about use outside the laboratory; dates and titles are given so that each paper can be located and read directly. For compound-level information on mechanism, structure and handling see the GHK-Cu research overview; this page is about how the knowledge accumulated.
The early 1970s: a growth-modulating tripeptide
The record begins with work on factors in human plasma that influence the behavior of cultured liver cells. A 1973 paper described a synthetic tripeptide that increased the survival of normal liver cells in culture and stimulated the growth of hepatoma cells (Pickart et al., 1973). In 1979 the group published a structure-activity study of the plasma tripeptide, examining how molecular structure related to DNA synthesis in hepatoma cells (Pickart and Thaler, 1979). The sequence was glycyl-L-histidyl-L-lysine. The papers are significant because they established a defined, synthesizable three-residue peptide as the active entity, which made controlled experiments possible.
1980: the copper connection
The next step was the proposal that the tripeptide works by binding copper and delivering it to cells. The 1980 Nature paper reported that the growth-modulating tripeptide may function by facilitating copper uptake into cells (Pickart et al., 1980). That paper moved the tripeptide from a purely organic peptide into a metallopeptide, and it explains why the compound is written GHK-Cu. The title’s cautious verb (“may function”) is a reminder that the mechanism was a proposal, and later work has refined and extended rather than simply confirmed it.
1982: structure of the complex
A 1982 study used electron paramagnetic resonance and related spectroscopy to define how copper(II) is held in solution (Freedman et al., 1982). The result describes coordination by the histidine imidazole nitrogen, the N-terminal amine and a deprotonated backbone amide nitrogen in a square-planar arrangement. That structural picture underlies the later laboratory practice of controlling pH and avoiding chelators when working with the complex, and it is why the product’s color (blue in solution) is a convenient indicator of intact copper binding.
| Year | Publication | What it reported | Type of evidence |
|---|---|---|---|
| 1973 | Pickart et al., BBRC | Synthetic tripeptide increased survival of normal liver cells and stimulated hepatoma growth in culture | Cell culture |
| 1979 | Pickart and Thaler, FEBS Lett | Structure-activity relationships of the plasma tripeptide for DNA synthesis in hepatoma cells | Cell culture, structure-activity |
| 1980 | Pickart et al., Nature | Proposed function by facilitating copper uptake into cells | Cell culture, chemistry |
| 1982 | Freedman et al., Biochemistry | Structure of the GHK-copper(II) complex in solution | Spectroscopy |
| 2000 | Siméon et al., Life Sci | Complex stimulated matrix metalloproteinase-2 expression in fibroblast cultures | Cell culture |
The 1990s and 2000: fibroblasts and matrix
Research then broadened to extracellular matrix biology, where fibroblast cultures are the natural model. A 2000 study reported that the GHK-copper complex stimulated expression of matrix metalloproteinase-2 in fibroblast cultures (Siméon et al., 2000). That work, along with related reports from the same period, tied the peptide to matrix turnover rather than to growth modulation alone, and it set the template for later readouts: expression of matrix enzymes, their inhibitors and structural proteins in cultured cells. Details of what those endpoints involve are in the GHK-Cu copper peptide research article.
2008 to 2015: reviews consolidate the field
From 2008 a series of review articles collected the literature and framed it in terms of tissue remodeling, skin biology and oxidative stress. A 2008 review discussed the tripeptide’s role in tissue remodeling (Pickart, 2008). A 2015 review summarized reported actions on multiple cellular pathways in skin regeneration models (Pickart et al., 2015). These are authoritative sources, but they are reviews written largely by researchers closely involved with the compound, so independent replication of individual findings is an important companion to them. The articles on GHK-Cu explained and GHK-Cu versus other copper peptides give broader context.
2018: the gene-expression turn
The latest wave of work used large public gene-expression datasets. A 2018 review presented the gene-expression findings as a framework for the reported regenerative and protective actions (Pickart and Margolina, 2018). The approach is computational: expression signatures associated with the peptide in reference databases are compared with signatures of disease states. It generates hypotheses about which pathways the peptide may influence, but signatures do not themselves demonstrate function, a limitation worth keeping in mind when these papers are cited.
| Era | Dominant question | Main method | Limits |
|---|---|---|---|
| 1970s | What is the active factor and does it alter cell growth? | Cell culture, peptide synthesis | Cell-line specific, narrow endpoints |
| 1980–1982 | How does it work and what is its structure? | Copper uptake assays, spectroscopy | Solution chemistry, not cells in tissue |
| 1990s–2000 | Does it affect matrix? | Fibroblast cultures | In vitro only |
| 2008–2015 | What is the whole picture? | Reviews | Largely from one research network |
| 2017–2018 | Which genes and pathways? | Database analysis of expression signatures | Associative; needs wet-lab confirmation |
Naming and terminology
Several names circulate for the same material, and clarity about them avoids mistakes when searching the literature. The peptide is glycyl-L-histidyl-L-lysine, abbreviated GHK. Bound to copper it is GHK-Cu, also written as the copper tripeptide or copper(II) glycyl-histidyl-lysine. The product catalog lists the compound as copper tripeptide-1 with a sequence of Gly-His-Lys (copper-bound). Literature searches for the free peptide and for the complex return different sets of papers, because many experiments compare the two. A paper that uses “GHK” without copper may not be studying the same species as one that uses “GHK-Cu”, and the distinction should be tracked when a result is carried from one paper into a new design.
Reading older papers critically
The 1970s and 1980s papers used techniques and standards of their time, which is normal for work of that period. Cell lines have since been re-authenticated, culture media have changed, and analytical characterization of peptides is far more rigorous today, with HPLC and mass spectrometry routinely reported (HPLC versus mass spectrometry). Older reports may not state the purity or the copper-to-peptide ratio of the material, and trace copper in culture serum can confound experiments. These are not reasons to discount the work, but they are reasons to confirm key results with well-characterized material and appropriate controls, including a copper-free peptide arm and a copper-only arm.
What the history does and does not show
Three points emerge from reading the sequence of papers together. First, the compound has a continuous, if relatively narrow, research literature of roughly five decades, which means its chemistry is better characterized than that of many newer research peptides. Second, much of that literature is cell-culture or computational; that is appropriate for a research reagent but does not extend to claims beyond the laboratory. Third, because many of the key reviews share authors, a careful reader checks whether findings have been reproduced elsewhere. None of this reduces the practical value of GHK-Cu as a tool for studying copper-dependent signaling and matrix biology; it simply defines the evidence level.
Using the history in practical planning
The milestones map directly onto laboratory decisions. The copper-uptake proposal and structural work mean that experimental buffers should avoid chelators and extremes of pH. The fibroblast work suggests matrix enzymes and related genes as readouts. The gene-expression papers suggest transcriptomic profiling as a way of seeing the broad response. Concentration planning is formula-based (mg/mL equals vial mass in mg divided by diluent volume in mL; molar concentration divides by molar mass) and the calculator handles the volume side. The product page lists the supplied form (lyophilized powder, 50 mg and 100 mg sizes) and the storage instruction (refrigerate at 2–8 °C, −20 °C for long-term, protect from heat, moisture and light). Lot documents, where published, are in the COA library, and GHK-Cu purity testing explains the analytical side. For laboratory research use only.
Related reading
The same copper-peptide logic appears in blends: see the GHK-Cu versus KPV comparison and the Glow blend overview. For storage specifics, Glow reconstitution and storage applies the same chemistry to a multi-peptide preparation.
Frequently asked questions
Who first described GHK?
Work by Pickart and colleagues from the early 1970s described a growth-modulating tripeptide, glycyl-histidyl-lysine, and its effects in liver-cell cultures (1973, 1979).
When was copper linked to the peptide?
A 1980 Nature paper proposed that the tripeptide may function by facilitating copper uptake into cells.
How is copper held by the peptide?
A 1982 spectroscopic study described coordination of copper(II) by the histidine imidazole nitrogen, the N-terminal amine and a deprotonated backbone amide nitrogen.
Why is GHK-Cu blue in solution?
The copper(II) center absorbs light in the visible range, and the intensity depends on concentration.
What did fibroblast studies add?
A 2000 study reported stimulated expression of matrix metalloproteinase-2 in fibroblast cultures, tying the peptide to matrix turnover.
What are the 2008–2015 papers?
Review articles that collect the tissue-remodeling, oxidative-stress and skin-regeneration literature.
What is the gene-expression literature?
Analyses of public expression databases that associate the peptide with changes in many gene sets; they generate hypotheses and require wet-lab confirmation.
Is the literature independent?
Many key reviews share authors, so independent replication of individual findings is an important complement.
How should the vial be stored?
As the product page states: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
Where can I find the current product facts?
On the GHK-Cu product page, which lists sizes, purity, form and storage, and in the COA library where lot documents are published.
Related reading: GHK-Cu Antioxidant and Oxidative Stress Models, GHK-Cu Wound Healing Models: Preclinical Research, GHK-Cu Regenerative Research: An Evidence Map.
References
- Pickart L, Thayer L, Thaler M. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochem Biophys Res Commun. 1973;54(2):562-566. doi:10.1016/0006-291x(73)91459-9
- Pickart L, Thaler M. Growth-modulating human plasma tripeptide: relationship between molecular structure and DNA synthesis in hepatoma cells. FEBS Lett. 1979;104(1):119-122. doi:10.1016/0014-5793(79)81096-0
- Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. doi:10.1038/288715a0
- Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J. Structure of the glycyl-L-histidyl-L-lysine-copper(II) complex in solution. Biochemistry. 1982;21(19):4540-4544. doi:10.1021/bi00262a004
- Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-2265. doi:10.1016/s0024-3205(00)00803-1
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. doi:10.1163/156856208784909435
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
